GlaxoSmithKline Survives Technical Woes To Win US FDA Panel Nod For Belantamab

 
• By Sue Sutter

Benefits of the BCMA-directed antibody-drug conjugate outweigh its ocular risks in heavily pretreated multiple myeloma patients, Oncologic Drugs Advisory Committee says at the conclusion of a virtual meeting beset by technical problems.

Oncologic Drugs Advisry Committee Meeting has technical difficulties
FDA had to restart the ODAC meeting two hours after it originally began due to technical problems. • Source: Screen shot

GlaxoSmithKline plc overcame ocular toxicity concerns – and a host of technical problems – to score a US Food and Drug Administration panel endorsement for its multiple myeloma drug belantamab mafodotin during a trouble-filled virtual meeting on 14 July.

All of the members of the Oncologic Drugs Advisory Committee who remained at the meeting’s conclusion, more than 2

Advisory Committee Vote
  • Does the demonstrated benefit of belantamab mafodotin outweigh the risks in the proposed patient population with

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United States

More from North America